SPDMV

CAS No. 890409-85-5

SPDMV( —— )

Catalog No. M33559 CAS No. 890409-85-5

SPDMV is a PEG-based ADC linker involved in the synthesis of antibody-coupled reactive molecules (ADCs).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 71 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SPDMV
  • Note
    Research use only, not for human use.
  • Brief Description
    SPDMV is a PEG-based ADC linker involved in the synthesis of antibody-coupled reactive molecules (ADCs).
  • Description
    SPDMV is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Antibody Drug Conjugates (ADC)
  • Target
    ADCs Linker/Click Chemistry
  • Recptor
    ADC Linker
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    890409-85-5
  • Formula Weight
    354.44
  • Molecular Formula
    C15H18N2O4S2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (282.14 mM; Ultrasonic )
  • SMILES
    CC(C)(CCC(=O)ON1C(=O)CCC1=O)SSc1ccccn1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Daniel Teufel, et al. Bicyclic peptide-toxin conjugates specific for mt1-mmp. WO2017191460A1.
molnova catalog
related products
  • Fmoc-Val-Cit-PAB-PNP

    A cathepsin B-cleavable dipeptide linker for antibody-drug-conjugation (ADC).

  • BTTAA

    A Cu(I)-stabilizing ligand that shows high activity in accelerating the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC); BTTAA-Cu(I) catalyst is the optimal choice for cell surface azide-alkyne ligation, mediates CuAAC and copper-free click chemistry.

  • m-PEG12-amine

    m-PEG12-amine is a PEG-based PROTAC linker and a non-cleavable 12-unit PEG ADC linker used in the synthesis of PROTACs and antibody-drug conjugates (ADCs) .